ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

NCT03769506 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer

Interventions

COMBINATION_PRODUCT: ASP-1929 Photoimmunotherapy
DRUG: Physician's Choice SOC

Sponsor

Rakuten Medical, Inc.